Voyageur works on barium, iodine contrast drug BFS

Executive Summary

• Voyageur Pharmaceuticals provided a corporate update and strategic roadmap focusing on its vertically integrated supply chain for barium and iodine contrast media, aiming to address critical supply chain vulnerabilities in the diagnostic imaging sector.
• The company is advancing two Bankable Feasibility Studies (BFS): the Frances Creek (FC) barium project and the Bayer iodine project, with final BFS delivery targeted for the second half of 2026.
• Regulatory progress includes the commencement of the FDA 505(b)(2) approval process for barium in February 2026, with potential U.S. market entry by mid-to-late 2027, and plans to advance a generic iodine FDA license in the second half of 2026.

Key Details

• Frances Creek (FC) Barium Project:
  • Currently in the BFS phase; expected to be delivered in the second half of 2026 following geotechnical drilling studies.
  • Mineral resource: 132,000 tonnes of pharmaceutical-grade barium sulphate (indicated and inferred).
  • Recent testing confirms barite purity exceeds pharmaceutical grade at 97.5%, with an average grade of 98.8% BaSO4.
  • Preliminary Economic Assessment (PEA) valued the project at a Net Present Value (NPV) of $344 million.
  • Commercial validation: Generated approximately $32,000 in initial contrast product sales using imported barium sulphate via Alberta Veterinary Laboratories.
  • Product development completed for five Health Canada-approved barium products.
• Bayer Iodine Project:
  • Subject to successful completion of the BFS, Bayer and Voyageur may advance to a second phase involving an offtake-linked production financing arrangement.
  • Under this potential arrangement, Bayer would provide capital financing while Voyageur operates and manages the project.
  • Intellectual property developed remains exclusively owned by Voyageur.
  • LOI signed with Bayer on December 20, 2024.
• Iodine Drug Feasibility:
  • Independently advancing a prefeasibility study integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform.
  • Targets 35 million doses per year of iodine contrast drug production using iodine-rich brine from U.S. oil and gas operations.
  • The combined processes are expected to significantly lower manufacturing costs.
• Regulatory Pathways:
  • Barium: FDA submission documents drafted; formal approval process commenced via the 505(b)(2) pathway in February 2026. FDA pending requirements expected in Q1 2026. Review process anticipated to take ~10 months, with product testing at 6-7 months.
  • Iodine: Plans to advance a generic iodine FDA license in the second half of 2026.
  • Global approval from the FDA is expected to facilitate registration in the EU and other international markets.
• Financial and Strategic Outlook:
  • Voyageur aims to become the only vertically integrated radiology drug company globally ("earth to bottle").
  • Construction of the barium and iodine drug manufacturing facility is targeted to commence in 2027.
  • Company is reviewing financial options for future capital expenditures, targeting non-dilutive financing for the Bayer project and construction funding for its own manufacturing facility.
  • Market expansion efforts include developing international sales in Latin America, Middle East, North Africa, and Asia-Pacific.

Notable Quotes

• "Voyageur aims to address the critical supply chain vulnerabilities in the diagnostic imaging sector, where demand is projected to grow from $6.77-billion (U.S.) in 2024 to $13.86-billion (U.S.) by 2033."
• "Voyageur is committed to strengthening health care infrastructure and meeting the growing global demand for diagnostic imaging pharmaceuticals."
• "Management of the company believes these efforts will position Voyageur as the only vertically integrated manufacturer of barium and iodine contrast media globally, providing affordable and secure supplies for health care authorities worldwide."